For a listing of full articles please visit our NCBI page

2014

“The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios.”

Wobst HJ, Sharma A, Diamond MI, Wanker EE, Bieschke J.

FEBS Lett. 2014 Nov 28. pii: S0014-5793(14)00831-X. doi: 10.1016/j.febslet.2014.11.026. [Epub ahead of print]

 

2013

“Surface adsorption considerations when working with amyloid fibrils in multiwell plates and Eppendorf tubes.”

Murray AN, Palhano FL, Bieschke J, Kelly JW.

Protein Sci. 2013 Nov;22(11):1531-41. doi: 10.1002/pro.2339. Epub 2013 Sep 30. Erratum in: Protein Sci. 2013 Nov;22(11):1689.

 

Counting unstained, confluent cells by modified bright-field microscopy.

Drey LL, Graber MC, Bieschke J.

Biotechniques. 2013 Jul

 

Natural compounds may open new routes to treatment of amyloid diseases.

Bieschke J.

Neurotherapeutics. 2013 Jul;10

 

2012

“Structural Properties of EGCG-Induced, Nontoxic Alzheimer's Disease Aβ Oligomers.”

Lopez Del Amo JM, Fink U, Dasari M, Grelle G, Wanker EE, Bieschke J, Reif B.

J Mol Biol. 2012 Jan 28

 

2011

“Small-molecule conversion of toxic oligomers to nontoxic β-sheet-rich amyloid fibrils.”

Bieschke J, Herbst M, Wiglenda T, Friedrich RP, Boeddrich A, Schiele F, Kleckers D, Lopez del Amo JM, Grüning BA, Wang Q, Schmidt MR, Lurz R, Anwyl R, Schnoegl S, Fändrich M, Frank RF, Reif B, Günther S, Walsh DM, Wanker EE. (2011)

Nat Chem Biol. 2011 Nov 20;8(1):93-101.

 

“Black tea theaflavins inhibit formation of toxic amyloid-β and α-synuclein fibrils.”

Grelle G, Otto A, Lorenz M, Frank RF, Wanker EE, Bieschke J.

Biochemistry. 2011 Dec 13;50(49):10624-36. Epub 2011 Nov 16

 

“670  nm laser light and EGCG complementarily reduce amyloid-β aggregates in human neuroblastoma cells: basis for treatment of Alzheimer's disease?”

Sommer AP, Bieschke J, Friedrich RP, Zhu D, Wanker EE, Fecht HJ, Mereles D, Hunstein W.

Photomed Laser Surg. 2012 Jan;30(1):54-60. Epub 2011 Oct 26.

 

“Bacterial inclusion bodies of Alzheimer's disease β-amyloid peptides can be employed to study native-like aggregation intermediate states.”

Dasari M, Espargaro A, Sabate R, Lopez del Amo JM, Fink U, Grelle G, Bieschke J, Ventura S, Reif B.

Chembiochem. 2011 Feb 11;12(3):407-23. doi: 10.1002/cbic.201000602. Epub 2011 Jan 10.

 

2010

“EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity”

Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, Wanker EE.

Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7710-5. Epub 2010 Apr 12.

 

2009

“A kinetic assessment of the C. elegans amyloid disaggregation activity enables uncoupling of disassembly and proteolysis.”

Bieschke J, Cohen E, Murray A, Dillin A, Kelly JW.

Protein Sci. 2009 Nov;18(11):2231-41.

 

2008

“EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers.”

Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE.

Nat Struct Mol Biol. 2008 Jun;15(6):558-66. Epub 2008 May 30.

 

“Alzheimer's Abeta peptides containing an isostructural backbone mutation afford distinct aggregate morphologies but analogous cytotoxicity. Evidence for a common low-abundance toxic structure(s)?”

Bieschke J, Siegel SJ, Fu Y, Kelly JW.

Biochemistry. 2008 Jan 8;47(1):50-9. Epub 2007 Dec 14.

 

2007

 

“The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation.”

Siegel SJ, Bieschke J, Powers ET, Kelly JW.

Biochemistry. 2007 Feb 13;46(6):1503-10.

 

2006

“Amide-to-E-olefin versus amide-to-ester backbone H-bond perturbations: Evaluating the O-O repulsion for extracting H-bond energies.”

Fu Y, Gao J, Bieschke J, Dendle MA, Kelly JW.

J Am Chem Soc. 2006 Dec 20;128(50):15948-9.

 

 

“Small molecule oxidation products trigger disease-associated protein misfolding.”

Bieschke J, Zhang Q, Bosco DA, Lerner RA, Powers ET, Wentworth P Jr, Kelly JW.

Acc Chem Res. 2006 Sep;39(9):611-9.

 

“Opposing activities protect against age-onset proteotoxicity.”

Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A.

Science. 2006 Sep 15;313(5793):1604-10. Epub 2006 Aug 10.

 

“Structure-function-folding relationship in a WW domain.”

Jäger M, Zhang Y, Bieschke J, Nguyen, Dendle M, Bowman ME, Noel JP, Gruebele M, Kelly.

Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10648-53. Epub 2006 Jun 28.

 

2005

“E-olefin dipeptide isostere incorporation into a polypeptide backbone enables hydrogen bond perturbation: probing the requirements for Alzheimer's amyloidogenesis.”

Fu Y, Bieschke J, Kelly JW.

J Am Chem Soc. 2005 Nov 9;127(44):15366-7.

 

“Single particle detection and characterization of synuclein co-aggregation.”

Giese A, Bader B, Bieschke J, Schaffar G, Odoy S, Kahle PJ, Haass C, Kretzschmar H.

Biochem Biophys Res Commun. 2005 Aug 12;333(4):1202-10.

 

“Automated PrPres amplification using indirect sonication.”

Sarafoff NI, Bieschke J, Giese A, Weber P, Bertsch U, Kretzschmar HA.

J Biochem Biophys Methods. 2005 Jun 30;63(3):213-21.

 

“Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets.”

Bertsch U, Winklhofer KF, Hirschberger T, Bieschke J, Weber P, Hartl FU, Tavan P, Tatzelt J, Kretzschmar HA, Giese A.

J Virol. 2005 Jun;79(12):7785-91.

 

“Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation.”

Bieschke J, Zhang Q, Powers ET, Lerner RA, Kelly JW.

Biochemistry. 2005 Apr 5;44(13):4977-83.

 

2004

“Autocatalytic self-propagation of misfolded prion protein.”

Bieschke J, Weber P, Sarafoff N, Beekes M, Giese A, Kretzschmar H.

Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12207-11. Epub 2004 Aug 5.

 

“Metabolite-initiated protein misfolding may trigger Alzheimer's disease.”

Zhang Q, Powers ET, Nieva J, Huff ME, Dendle MA, Bieschke J, Glabe CG, Eschenmoser A, Wentworth P Jr, Lerner RA, Kelly JW.

 

2000

“Putting prions into focus: application of single molecule detection to the diagnosis of prion diseases.”

Giese A, Bieschke J, Eigen M, Kretzschmar HA.

Arch Virol Suppl. 2000;(16):161-71.

 

“Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets.”

Bieschke J, Giese A, Schulz-Schaeffer W, Zerr I, Poser S, Eigen M, Kretzschmar H.

Proc Natl Acad Sci U S A. 2000 May 9;97(10):5468-73.

 

“Differential constitutive and activation-dependent expression of prion protein in human peripheral blood leucocytes.”

Dürig J, Giese A, Schulz-Schaeffer W, Rosenthal C, Schmücker U, Bieschke J, Dührsen U, Kretzschmar HA.

Br J Haematol. 2000 Mar;108(3):488-95.

 

1998

 

“Aggregation of prion protein investigated by dual-color fluorescence cross-correlation spectroscopy.”
Fluorescent Microscopy and Fluorescent Probes, J.Slavik, ed 2 (1998) 81-86

 

“Rapid assay processing by integration of dual-color fluorescence cross-correlation spectroscopy: high throughput screening for enzyme activity.”

Koltermann A, Kettling U, Bieschke J, Winkler T, Eigen M.

Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1421-6.

Bieschke, J. & Schwille, P.

“Kinetic investigations by fluorescence correlation spectroscopy: the analytical and diagnostic potential of diffusion studies.”

Schwille, P., Bieschke, J. & Oehlenschläger, F.
Biophys Chem 66 (1997) 211-228

 

1997

 

“Kinetic investigations by fluorescence correlation spectroscopy: the analytical and diagnostic potential of diffusion studies.”

Schwille P, Bieschke J, Oehlenschläger F.

Biophys Chem. 1997 Jun 30;66(2-3):211-28.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

publications

Age-Related Protein Misfolding

Laboratory of Jan Bieschke, Ph.D.

Center for Biological and Systems Engineering

Age-Related Protein Misfolding

Laboratory of Jan Bieschke, Ph.D.

Center for Biological and Systems Engineering

Age-Related Protein Misfolding

Laboratory of Jan Bieschke, Ph.D.

Center for Biological and Systems Engineering